Squarepoint
ATRA icon

Squarepoint’s Atara Biotherapeutics ATRA Stock Holding History

Squarepoint’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,728
Closed -$175K – 3993
2023
Q3 		$175K Buy
4,728
+1,825
+63% +$81.2K ﹤0.01% 3453
2023
Q2 		$117K Sell
2,903
-1,368
-32% -$77.4K ﹤0.01% 3332
2023
Q1 		$310K Buy
4,271
+2,641
+162% +$256K ﹤0.01% 2552
2022
Q4 		$134K Sell
1,630
-6,526
-80% -$680K ﹤0.01% 2905
2022
Q3 		$771K Buy
+8,156
New +$916K ﹤0.01% 1939
2021
Q2 		– Sell
-4,754
Closed -$1.71M – 3212
2021
Q1 		$1.71M Buy
4,754
+2,095
+79% +$926K 0.01% 1154
2020
Q4 		$1.3M Buy
2,659
+442
+20% +$204K 0.01% 1169
2020
Q3 		$718K Sell
2,217
-3,384
-60% -$1.15M 0.01% 1192
2020
Q2 		$2.04M Buy
5,601
+4,034
+257% +$1.02M 0.03% 623
2020
Q1 		$333K Buy
1,567
+856
+120% +$272K 0.01% 1252
2019
Q4 		$293K Sell
711
-286
-29% -$98.6K ﹤0.01% 2050
2019
Q3 		$352K Buy
+997
New +$372K ﹤0.01% 1804
2019
Q2 		– Sell
-1,159
Closed -$1.15M – 2360
2019
Q1 		$1.15M Buy
1,159
+501
+76% +$465K 0.01% 1029
2018
Q4 		$571K Sell
658
-294
-31% -$273K 0.01% 1180
2018
Q3 		$984K Sell
952
-464
-33% -$454K 0.01% 994
2018
Q2 		$1.3M Buy
1,416
+968
+216% +$1.04M 0.02% 791
2018
Q1 		$437K Sell
448
-370
-45% -$337K 0.01% 1139
2017
Q4 		$370K Buy
+818
New +$302K 0.01% 1374
2017
Q1 		– Sell
-407
Closed -$145K – 1519
2016
Q4 		$145K Buy
+407
New +$172K 0.01% 1548
2016
Q2 		– Sell
-648
Closed -$308K – 1094
2016
Q1 		$308K Buy
648
+336
+108% +$151K 0.02% 813
2015
Q4 		$206K Buy
+312
New +$236K 0.02% 981

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's ATRA Position: Q4 2023 in Review

Squarepoint sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 4,728 shares — an estimated $175K sold.

Squarepoint first reported a position in ATRA in Q4 2015 and held it in 21 quarters. The position peaked at $2.04M in Q2 2020. 90 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • Squarepoint reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Squarepoint sold 4,728 Atara Biotherapeutics shares in Q4 2023, an estimated $175K.
  • Squarepoint first reported a position in Atara Biotherapeutics in Q4 2015 and held it in 21 quarters.
  • Squarepoint's Atara Biotherapeutics position peaked at $2.04M in Q2 2020.
  • 90 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on Squarepoint's 13F filing for Q4 2023, filed 14 Feb 2024.